Epigenetic editing was used to reduce the activity of a gene that affects cholesterol levels without changing the DNA sequence — and did so for an extended period, according to a study in mice by Cappelluti and colleagues. The study lays the foundation for the development of in vivo therapeutics that are based on epigenetic silencing. …

Cappelluti, M.A., Mollica Poeta, V., Valsoni, S. et al. Durable and efficient gene silencing in vivo by hit-and-run epigenome editing. Nature (2024). https://doi.org/10.1038/s41586-024-07087-8

https://www.nature.com/articles/s41586-024-07087-8

https://www.nature.com/articles/d41586-024-00563-1

and see also:

Ueda J, Yamazaki T, Funakoshi H. Toward the Development of Epigenome Editing-Based Therapeutics: Potentials and Challenges. Int J Mol Sci. 2023 Mar 1;24(5):4778. doi: 10.3390/ijms24054778. PMID: 36902207; PMCID: PMC10003136.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003136/